Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study
Cusato, Jessica
Co-first
;De Nicolò, AmedeoCo-first
;Boglione, Lucio;Favata, Fabio;Ariaudo, Alessandra;Mornese Pinna, Simone;Carcieri, Chiara;Avataneo, Valeria;Di Perri, Giovanni;D'Avolio, AntonioLast
2018-01-01
Abstract
Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN) outcomes.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
dky053.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
359.13 kB
Formato
Adobe PDF
|
359.13 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
